Stallergenes : Investor Meeting: Webcast is Available

March 25, 2009

PARIS, March 25 /PRNewswire-FirstCall/ — Hello,

The investor meeting relating to the 2008 earnings and 2009 outlook has
been webcasted. The presentation is available in English from the following



(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser’s URL address field. Remove the
space if one exists.)


Stallergenes is a European biopharmaceutical company dedicated to
desensitization therapies for the prevention and treatment of allergy-related
respiratory diseases, e.g. rhinoconjunctivitis and allergic asthma. A pioneer
and leader in sublingual desensitization treatments, Stallergenes devotes 21%
(gross) of its sales to Research and Development and is actively involved in
the development of a new therapeutic class: sublingual desensitization

In 2008, Stallergenes had sales of EUR 171 million and provided
desensitization treatments to more than 500,000 patients.

    Euronext Paris (Compartment B)
    SBF 120.
    ISIN Code: FR0000065674
    Reuters Code: GEN.PA
    Bloomberg Code: GEN.FP

Additional financial information is available at

SOURCE Stallergenes

Source: newswire

comments powered by Disqus